Thanou-Stavraki Aikaterini, Sawalha Amr H
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA;
Biologics. 2011;5:33-43. doi: 10.2147/BTT.S13804. Epub 2011 Feb 14.
B-lymphocyte stimulator (BLyS), a homeostatic factor for B-cell differentiation and survival, has a major role in B-cell expansion and autoreactivity that characterize systemic lupus erythematosus (SLE). Belimumab, a BLyS-specific inhibitor, has shown promising evidence of efficacy in several preclinical and clinical studies in SLE. Two recent large randomized controlled trials yielded a significant positive effect of the drug compared to placebo in patients with active disease. In this review, we discuss basic aspects of B-cell and BLyS biology in SLE and summarize the evidence supporting a role of belimumab in SLE, from animal studies to phase III clinical trials.
B淋巴细胞刺激因子（BLyS）是B细胞分化和存活的稳态因子，在系统性红斑狼疮（SLE）所特有的B细胞扩增和自身反应性中起主要作用。贝利尤单抗是一种BLyS特异性抑制剂，在SLE的多项临床前和临床研究中已显示出有前景的疗效证据。最近两项大型随机对照试验表明，与安慰剂相比，该药物对活动性疾病患者有显著的积极效果。在本综述中，我们讨论了SLE中B细胞和BLyS生物学的基本方面，并总结了从动物研究到III期临床试验支持贝利尤单抗在SLE中作用的证据。
